Spa therapy induces clinical improvement and protein changes in patients with chronic back pain by Angioni, MM et al.
Reumatismo 3/2019 119
ORIGINAL
PAPERReumatismo, 2019; 71 (3): 119-131
SUMMARY
This study is primarily aimed at assessing serum changes on a large panel of proteins in patients with chronic 
back pain following spa therapy, as well as evaluating different spa therapy regimens as a preliminary explora-
tory clinical study.
Sixty-six patients with chronic back pain secondary to osteoarthritis were randomly enrolled and treated with 
daily mud packs and bicarbonate-alkaline mineral water baths, or a thermal hydrotherapy rehabilitation scheme, 
the combination of the two regimens or usual medication only (control group), for two weeks. Clinical variables 
were evaluated at baseline, after 2 and 12 weeks. One thousand serum proteins were tested before and after a 
two-week mud bath therapy.
All spa treatment groups showed clinical benefit as determined by improvements in VAS pain, Roland Mor-
ris disability questionnaire and neck disability index at both time points. The following serum proteins were 
found greatly increased (≥2.5 fold) after spa treatment: inhibin beta A subunit (INHBA), activin A receptor 
type 2B (ACVR2B), angiopoietin-1 (ANGPT1), beta-2-microglobulin (B2M), growth differentiation factor 
10 (GDF10), C-X-C motif chemokine ligand 5 (CXCL5), fibroblast growth factor 2 (FGF2), fibroblast growth 
factor 12 (FGF12), oxidized low density lipoprotein receptor 1 (OLR1), matrix metallopeptidase 13 (MMP13). 
Three proteins were found greatly decreased (≤0.65 fold): apolipoprotein C-III (Apoc3), interleukin 23 alpha 
subunit p19 (IL23A) and syndecan-1 (SDC1).
Spa therapy was confirmed as beneficial for chronic back pain and proved to induce changes in proteins in-
volved in functions such as gene expression modulation, differentiation, angiogenesis, tissue repair, acute and 
chronic inflammatory response.
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n	 INTRODUCTION
Salus per aquam (spa) therapy repre-sents a popular treatment for several 
rheumatic diseases, such as axial and pe-
ripheral osteoarthritis, fibromyalgia and 
extra-articular rheumatisms (1-6), but also 
for chronic arthritis as adjunctive therapy, 
such as in spondyloarthritis and rheuma-
toid arthritis (7-10). 
The therapeutic beneficial effects of spa 
treatments are believed to be mainly due 
to the intrinsic water physical/chemical 
features. Thermal mineral water contains 
solutes such as cations (i.e. calcium, mag-
nesium, sodium and potassium) and ani-
ons (bicarbonates, sulphates, chloride) at 
a minimum concentration of at least 1 g/L 
(11). Thermal water effects appear there-
fore mediated by the physical and chemi-
cal properties of water by means of me-
chanical and thermal effects together with 
the absorption of mineral solutes which 
are believed to contribute to the beneficial 
effects on the inflammatory pathway and 
bone metabolism, recently summarized by 
Fioravanti et al. (12) and Cozzi et al. (13). 
A very popular way to deliver balneologi-
cal therapy is also by means of mud pack, 
which is defined as a natural mixture of 
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mineral water with organic or inorganic 
material (i.e. clay) and delivered in the 
form of mud wrap (14).
Spinal diseases and chronic back pain (15) 
are the most prevalent musculoskeletal con-
ditions which affect, during lifetime, the 
vast majority of the population. Back pain 
is regarded as chronic when it lasts longer 
than two/three months (16). The scien-
tific literature dedicated to spa therapy in 
chronic back pain has been reviewed in the 
past (17, 18). The beneficial effects have 
also been underlined by Balogh et al. (19) 
and by Kulisch et al. (20). Tefner et al. (21) 
have conducted a single blind randomized 
controlled trial demonstrating the beneficial 
effects of balneotherapy compared to tap 
water, while more recently Gáti et al. (22) 
have confirmed the therapeutic effects of the 
calcium-magnesium-bicarbonate thermal 
water, both studies in chronic low back pain.
A less frequent cause of chronic back pain 
is represented by ankylosing spondylitis 
(AS) (23), a systemic inflammatory chron-
ic disease affecting primarily the spine and 
affecting a younger population. In the later 
stage of disease, AS patients often present 
new bone formation such as bridging syn-
desmophytes which may result in a stiff 
spine and the development of a clinical 
picture characterized by mechanical back 
pain rather than the previous inflammatory 
back pain. 
Given the solid background present in the 
literature, the primary aim of this study was 
to evaluate serum changes on a large spec-
trum (one thousand) of proteins in patients 
with chronic back pain following MBT 
therapy. Furthermore, we also performed 
a preliminary exploratory study testing 
the clinical effects of different spa therapy 
regimens.
n	 MATERIALS AND METHODS
A cohort of 66 chronic back pain second-
ary to axial osteoarthritis (axOA) patients 
were included in this study. 46 patients 
(31F/15M) underwent spa therapy and 20 
patients (13F/7M), as a control group, were 
treated according to their usual regime. 
Furthermore, 11 patients with chronic back 
pain secondary to axial spondyloarthritis 
(ankylosing spondylitis), with inactive in-
flammatory disease, were also treated as 
parallel group. The study was conducted at 
the Antiche Terme di Sardara (VS Sardegna 
- Italy), which provided all the facilities for 
mud treatment and balneotherapy (MBT) 
and the thermal hydrotherapy rehabilita-
tion scheme (HRS). Ethical approval was 
granted by the local NHS authority ASL6 
prot. 2012/0021248, and was in accordance 
with the 1964 Helsinki declaration and its 
later amendments or comparable ethical 
standards. All patients participated in the 
study on a voluntary basis, providing in-
formed consent, according to good clinical 
practice. The mean age was 64.5±11.4 and 
BMI was 24.2±2.0 in the axOA spa therapy 
group; the mean age was 63.3±6.9 and the 
BMI 22.4±2.6 in the axOA control group. 
In the AS group the sex ratio (2F/9M) and 
mean age 50.5±10.8 were lower in accord-
ance with the epidemiology of the disease 
and the BMI was 23.9±2.5. All patients 
were on stable medication. Patients with 
the following co-pathologies were not in-
cluded in the study: evolving cardiovas-
cular diseases, cancer, infection, uncon-
trolled diabetes mellitus, severe lung or 
kidney disease, joint swelling or effusion, 
arthroprosthesis carrier, neurologic severe 
diseases, peripheral vascular diseases, any 
medical condition or pharmacologic treat-
ment that, according to the enrolling physi-
cian, should contraindicate participation in 
the study. Furthermore, subjects who had 
spa treatments in the previous 6 months 
were also excluded. All patients were Cau-
casian and were resident in the nearby area 
of the spa resort.
The patients were treated daily for two 
weeks according to two different thermal 
therapeutic interventions:
1) a combination of mud packs applied on 
the body surface at girdles and spine 
for 20 min at an initial temperature of 
45°C followed by bicarbonate-alkaline 
mineral water bath (Table I) at 38°C for 
10 min, and by 45 min of rest (mud bath 
therapy scheme, MBT), for a total of 12 
applications carried out over a period of 
2 weeks; and/or
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2) a thermal hydrotherapy rehabilitation 
scheme (HRS) which included stretches 
and strengthening exercises, floating or 
standing in the thermal pool (water tem-
perature 34°C). Upper and lower limbs, 
girdles, lower back, trunk and neck were 
involved in the exercise program. 45- to 
60-minute sessions according to person-
al physical endurance were supervised 
by professional rehabilitation staff daily, 
12 times over a two-week period.
Group A (12 patients with axOA) was 
treated with MBT only, group B (16 pa-
tients with axOA) was treated by the com-
bination of MBT and HRS, group C (18 
patients with axOA) was treated with HRS 
only. Twenty axOA patients had no thermal 
treatments, remained in their usual medi-
cations and were included in the control 
group. Patients were recruited randomly 
according to Zelen (24), following referral 
from a general practitioner (GP). The dis-
tinct group of 11 AS patients was treated 
by HRS only. 
Clinical assessment at baseline and fol-
low-up visits at two weeks (T2W) and 12 
weeks (T12W) included detailed objective 
examination and medical history, as well as 
evaluation of specific clinical domains by 
means of the following instruments: visual 
analogue scale (VAS) for pain (0=no pain, 
10=maximum pain), short form health sur-
vey of 36 items (SF-36) (25) referring to 
physical and mental components (quality 
of life) in all patients; Roland and Morris 
Disability Questionnaires (26) and Neck 
Disability Index (27), for axial involve-
ment in axOA chronic back pain. Bath 
Ankylosing Spondylitis Metrology/Func-
tional/Disease activity indexes (BASMI, 
BASFI and BASDAI) were administered 
to AS patients (28).
In order to study protein changes following 
spa treatment, MBT was selected as being 
the most diffuse and traditionally employed 
regimen across Europe, although the ther-
mal water component, which is believed to 
be responsible of the therapeutic effect of 
spa therapy, is the base of all the three regi-
mens clinically assessed. The MBT group 
was also selected for the proteomic study 
in order to avoid the physical exercise bias 
present in the other two groups. Blood 
samples from the patients enrolled in the 
study were collected by venipuncture, im-
mediately centrifuged and the serum was 
stored at –30°C until analyzed. For the 
proteomic analysis, patients’ sera from the 
MBT group were pooled in two different 
sample mixtures in order to have biologi-
cal replicates. The two pools of sera were 
representative of the male:female ratio and 
age distribution of the entire cohort. Serum 
proteins (listed in the supplementary data, 
see Appendix) were profiled using a semi-
quantitative method by the biotin-labeled-
based protein array (RayBio® L-Series Hu-
man Antibody Array 1000), following the 
manufacturer’s instructions. Once the glass 
slides were dried, laser fluorescence scan-
ning was used to visualize signals. The im-
ages were captured using an Axon GenePix 
laser scanner and are available in the Ap-
pendix. After subtracting background sig-
nals and normalization to positive controls, 
Table I - Chemical and physical characteristics of thermal water. 
Bicarbonates 26.0 meq/L
Calcium 27.0 mg/L
Chlorides 530.0 mg/L
Iron 0.30 mg/L
Fluorides 10.1 mg/L
Magnesium 6.6 mg/L
Nitrates 1.4 mg/L
Nitrites 0.020 mg/L
Potassium 41.0 mg/L
Silica 55.6 mg/L
Sodium 1220.0 mg/L
Sulphate 56.0 mg/L
Phosphates 0.0 mg/L
Free carbon dioxide 115.0 mg/L
Electrical conductivity (at 20°C) 3380 micrS/cm
Oxidizability 0.8 mgO2/L
pH 7.4 adimens
Fixed residue (at 180°) 2425 mg/L
Chemical and physical characteristics of the Sardara thermal water employed 
in this study (sodium bicarbonate alkaline water, 56.4°C).
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comparison of signal intensities between 
array images was employed to determine 
relative differences in expression levels of 
each protein between groups. According to 
the manufacturer’s technical datasheet, any 
≥2.5-fold increase or ≤0.65-fold decrease 
in signal intensity for a single analyte was 
considered a measurable and significant 
difference in expression, provided that 
both sets of signals were well above back-
ground (mean background + 2 standard 
deviations, accuracy ≈95%). Proteome data 
analysis was performed using the Analysis 
Tool Software for RayBio® Human Biotin-
Label Based Antibody Arrays, which au-
tomatically normalize signal intensities to 
the array’s positive controls. The results are 
shown in terms of fold increase or decrease 
between the end of treatment (T2W) and 
the baseline.
For the in silico interactome analysis, 
STRING open-access software (27) was 
used to analyze multiple protein-protein in-
teractions (https://string-db.org/). STRING 
software scores are indicators of confi-
dence, i.e. how likely STRING judges an 
interaction to be true, given the available 
evidence. All scores rank from 0 to 1, with 
1 being the highest possible confidence. A 
score of 0.5 would indicate that roughly 
every second interaction might be errone-
ous (i.e., a false positive). Demographic 
and clinical data have been expressed as 
mean ±SD. The Wilcoxon test was used to 
compare baseline data with data obtained 
after treatment at 2 and 12 weeks. P values 
less than 0.05 were considered statistically 
significant. Statistical analysis has been 
performed with the GraphPad Prism soft-
ware V 5.0. 
n	 RESULTS
In this study we investigated the effect of 
thermal water treatments in spa environ-
ment in patients with chronic back pain, 
focusing on changes induced in serum pro-
teins by analyzing, before and after MBT, 
one thousand different serum proteins cov-
ering the principal physiological functions.
The whole cohort of spa-treated axOA 
patients (46 subjects) showed a clear-cut 
benefit both after two weeks and after 12 
weeks compared with baseline, while no 
improvements were observed in the axOA 
control group (20 subjects). To sum up, 
in the whole cohort of spa-treated axOA 
patients we found: VAS pain at baseline 
6.2±1.6, T2W 3.4±1.3 and T12W 4.5±1.5 
(baseline vs T2W p=0.0001, baseline vs 
T12W p=0.0001). Neck disability index at 
baseline was 62.1±10.4, T2W 37.3±13.6 
and T12W 44.7±12.2 (baseline vs T2W 
p=0.0001, baseline vs T12W p=0.0001). 
Roland Morris index at baseline was 
15.6±3.7, T2W 7.7±2.9 and T12W 
10.9±4.0 (baseline vs T2W p=0.0001, 
baseline vs T12W p=0.0001). Detailed 
results in all axOA treatment groups and 
axOA controls are shown in Table II; be-
cause of the limited number of patients, in-
ter-groups comparison was not performed.
As a parallel group, 11 patients with 
chronic back pain secondary to AS, with 
inactive inflammatory disease, were also 
treated with the HRS, similarly to group 
C. In detail: VAS pain at baseline was 
6.3±2.2, T2W 3.8±2.7 and T12W 2.9±2.3 
(baseline vs T2W p=0.021, baseline vs 
T12W p=0.005). BASMI at baseline was 
5.3±2.6, T2W 3.2±2.0 and T12W 3.4±2.1 
(baseline vs T2W p=0.005, baseline vs 
T12W p=0.014). BASDAI at baseline was 
5.1±2.8, T2W 2.9±2.7 and time T12W 
2.6±1.5 (baseline vs T2W p=0.005, base-
line vs T12W p=0.001). BASFI at base-
line was 4.0±1.6, T2W 2.6±1.6 and time 
T12W 3.0±1.3 (baseline vs T2W p=0.014, 
baseline vs T12W p=0.018). SF-36 PC at 
baseline was 34.7±9.2, T2W 39.2±12.3 
and T12W 40.6±14.6 (baseline vs T2W 
p=ns, baseline vs T3M p=ns); SF-36 MC 
at baseline was 43.8±10.8, T2W 51.5±11.7 
and T12W 54.8±12.0 (baseline vs T2W 
p=0.005, baseline vs T12W p=0.042).
In this study we applied a proteomic ap-
proach to evaluate the effects of MBT 
(avoiding the bias of physical exercise) on a 
large spectrum of serum proteins in patients 
with chronic back pain secondary to osteo-
arthritis. Profiling 1000 serum proteins (the 
full list of tested proteins is shown as a sup-
plementary file, see Appendix) we found 
13 serum proteins (listed in Table III with 
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details of their biological functions) that 
were greatly modulated (≥2.5-fold increase 
or ≤0.65 fold decrease) comparing baseline 
and the end of 2 weeks of MBT treatment 
in both biological replicates. The fold vari-
ation that was not measured concordantly 
in both biological replicates, was not con-
sidered valid and the relative proteins were 
excluded. In detail, the following serum 
proteins were found to be greatly increased 
after spa treatment: inhibin beta A subu-
nit (INHBA), activin A receptor type 2B 
(ACVR2B), angiopoietin-1 (ANGPT1), 
beta-2-microglobulin (B2M), growth dif-
ferentiation factor 10 (GDF10), C-X-C mo-
tif chemokine ligand 5 (CXCL5), fibroblast 
growth factor 2 (FGF2), fibroblast growth 
factor 12 (FGF12), oxidized low density 
lipoprotein receptor 1 (OLR1), matrix met-
allopeptidase 13 (MMP13). The follow-
ing three proteins were greatly decreased: 
apolipoprotein C-III (Apoc3), interleukin 
23 alpha subunit p19 (IL23A) and synde-
can-1 (SDC1).
Apart from the possible specific role and 
functions of each single overexpressed or 
downregulated protein, which are summa-
rized in Table III, we also underline the pos-
sible protein-protein interactions. As shown 
in Figure 1, the in silico analysis of inter-
action between multiple proteins showed 
some interesting and strong data-supported 
connections between 10 out of 13 proteins 
changed after MBT treatment (Figure 1A). 
Expanding the panoramic view to other sec-
ondary predicted interactions around these 
proteins, the network was amplified as a re-
sult of software input by a maximum of 5 
Table II - Changes in clinical data following spa treatments.
Treatment regimen Domain/instrument Baseline 2 Weeks 12 Weeks
Group A
MBT
Vas PAIN 5.3±1.0 2.7±0.9 p=0.001 4.0±1.0 p=0.003
Neck disability index 57.7±9.4 36.7±8.5 p=0.035 46.1±9.7 p=0.031
Roland Morris 15.0±4.5 7.0±4.6 p=0.035 10.2±4.9 p=0.031
SF-36 PC 37.2±4.9 46.8±3.0 p=0.005 42.0±3.6 p=0.002
SF-36 MC 43.7±7.1 44.3±5.5 p=ns 41.3±5.8 p=ns
Group B
MBT + HRS
Vas PAIN 5.5±1.3 3.0±1.4 p=0.001 3.8±1.6 p=0.003
Neck disability index 66.7±7.6 40.1±16.7 p=0.014 44.2±17.3 p=0.007
Roland Morris 14.2±2.4 6.6±2.6 p=0.014 9.0±2.4 p=0.014
SF-36 PC 35.2±7.2 44.8±8.2 p=0.000 40.0±8.0 p=0.005
SF-36 MC 41.5±7.3 43.5±8.5 p=0.021 42.9±7.3 p=ns
Group C
HRS
Vas PAIN 7.4±1.5 4.1±1.1 p=0.000 5.4±1.3 p=0.000
Neck disability index 60.7±13.0 34.7±14.5 p=0.015 44.2±8.0 p=0.001
Roland Morris 17.0±3.9 8.9±2.5 p=0.003 12.7±4.0 p=0.006
SF-36 PC 32.2±6.2 44.7±6.0 p=0.000 38.3±4.7 p=0.000
SF-36 MC 41.3±8.0 41.6±8.5 p=ns 41.9±7.2 p=ns
Control group
NO spa therapy
Vas PAIN 6.4±1.8 6.1±1.5 p=ns
Neck disability index 55.5±16.0 52.3±14.6 p=ns
Roland Morris 15.9±3.0 15.1±3.4 p=ns
SF-36 PC 45.0±6.0 41.9±5.5 p=ns
SF-36 MC 43.0±6.0 43.0±7.0 p=ns
Changes in clinical data following spa treatments in the different axOA groups according to: VAS pain, Neck disability index, Roland 
Morris disability questionnaire, Short form healthy survey 36 items (SF-36) physical and mental components (PC and MC, respec-
tively). Because of the limited number of patients, inter-groups comparison was not performed. Abbreviations: Mud bath therapy 
(MBT), Hydrotherapy rehabilitation scheme (HRS), axial osteoarthritis (axOA).
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proteins around each node (Figure 1B). To 
verify how likely STRING software judges 
an interaction to be true (given the available 
evidence), we reported in Table IV all rank 
of confidence scores assigned automatically 
by the software.
n	 DISCUSSION  
AND CONCLUSIONS
The aim of the clinical part of this study 
was not to prove the efficacy of spa ther-
apy in chronic back pain, which has been 
Table III - List of serum proteins dysregulated after MBT treatment and their functions. 
L-series array 
name Full-name protein Protein annotations Fold
IL-23 Interleukin 23,  
alpha subunit p19
(IL23A)
Associates with IL12B to form the IL-23 interleukin, a heterodimeric  
cytokine which functions in innate and adaptive immunity. IL-23 induces 
inflammation and is involved in immune mediated inflammatory diseases.
0.4
Syndecan-1 Syndecan-1  
(SDC1)
Cell surface proteoglycan that bears both heparan sulfate and chondroitin 
sulfate and that links the cytoskeleton to the interstitial matrix.  
Regulates exosome biogenesis in concert with SDCBP and PDCD6IP.
0.5
ApoC3 Apolipoprotein C-III
(APOC3)
Component of triglyceride-rich very low-density lipoproteins (VLDL)  
and high-density lipoproteins (HDL) in plasma. Plays a multifaceted role  
in triglyceride homeostasis.
0.6
BMP-3b /  
GDF-10
Growth differentiation 
factor 10  
(GDF10)
Involved in osteogenesis and adipogenesis. Plays an inhibitory role  
in the process of osteoblast differentiation via SMAD2/3 pathway,  
and in the process of adipogenesis.
2.5
Activin A Inhibin beta A subunit 
(INHBA)
Regulates a number of diverse functions such as hypothalamic  
and pituitary hormone secretions including follitropin.
2.7
FGF Basic Fibroblast growth factor 
2 (FGF2)
Regulation of cell survival, cell division, angiogenesis, cell differentiation  
and cell migration. Functions as potent mitogen in vitro.
2.7
Angiopoietin-1 Angiopoietin-1
(ANGPT1)
Regulation of angiogenesis, endothelial cell survival, proliferation,  
migration, adhesion and cell spreading, reorganization of the actin 
cytoskeleton, but also maintenance of vascular quiescence.
3.2
FGF-12 Fibroblast growth factor 
12 (FGF12)
Involved in nervous system development and function. 3.2
pro-MMP13 Matrix metallopeptidase 
13 (MMP13)
Degradation of extracellular matrix proteins including fibrillar collagen, 
fibronectin, TNC and ACAN. Plays a role in wound healing, tissue remodeling, 
cartilage degradation, bone development, bone mineralization  
and ossification.
4.2
ENA-78 C-X-C motif chemokine 
ligand 5 (CXCL5)
Involved in neutrophil activation. 4.2
Activin RII A/B Activin A receptor  
type 2B (ACVR2B)
Transduces the activin signal from the cell surface to the cytoplasm  
and thus regulates many physiological and pathological processes including 
wound healing, extracellular matrix production, immunosuppression  
and carcinogenesis.
4.2
LOX-1 Oxidized low  
density lipoprotein 
receptor 1
(OLR1)
Marker of atherosclerosis that induces vascular endothelial cell activation  
and dysfunction, resulting in pro-inflammatory responses,  
pro-oxidative conditions and apoptosis.
Also involved in inflammatory process.
34.9
Beta 2M Beta-2-microglobulin
(B2M)
Component of the class I major histocompatibility complex (MHC).  
Involved in the presentation of peptide antigens to the immune system.
55.8
Results are expressed as mean of fold increase (≥2.5) or decrease (≤0.65) comparing baseline and 2-week therapy serum samples, 
concordantly in both biological replicates. 
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already demonstrated in large cohorts of 
patients as previously summarized, but to 
explore different treatment regimens as a 
preliminary approach to future studies.
The results emerging from this study, al-
though with the limitations due to the small 
number of patients enrolled in each group, 
allow several clinical observations to be 
drawn as to the beneficial effects of differ-
ent spa treatment regimens in chronic back 
pain and provide novel data regarding pro-
tein changes following MBT, by means of 
a widespread proteomic approach. To sum 
up, we found a clear clinical benefit, as as-
sessed by VAS pain, Neck disability index, 
Roland Morris disability questionnaire and 
SF-36 PC in axOA patients following spa 
intervention for all the three regimens em-
ployed. Because of the limited number of 
patients, inter-groups comparison was not 
performed.
Figure 1 - In silico multiple-proteins interaction analysis (STRING 
software V 10.5). Network nodes represent proteins, edges represent 
protein-protein association (line thickness indicates the strength of 
data support). Panel A shows the first-grade association between the 
13 proteins dysregulated after MBT treatment, in panel B the number 
of proteins is expanded to secondary interactions.
Table IV - Browse interactions in tabular form.
Node 1 Node 2 Score
ACVR2B GDF10 0.52
ACVR2B INHBA 0.99
ANGPT1 FGF2 0.70
APOC3 SDC1 0.90
CXCL5 IL23A 0.41
FGF2 ANGPT1 0.70
FGF2 INHBA 0.54
FGF2 MMP13 0.72
FGF2 SDC1 0.98
GDF10 ACVR2B 0.52
INHBA ACVR2B 0.99
INHBA FGF2 0.54
IL23A CXCL5 0.41
MMP13 FGF2 0.72
SDC1 APOC3 0.90
SDC1 FGF2 0.98
In STRING software, each protein-protein interac-
tion is annotated with one or more scores. These 
scores are indicators of confidence, all scores rank 
from 0 to 1, with 1 being the highest possible con-
fidence. A score of 0.5 would indicate that roughly 
every second interaction might be erroneous (i.e., a 
false positive).
In contrast, we did not find any clinical 
change in the control group of patients 
that continued with standard medication 
and did not receive spa or physiotherapy. 
It is also of note that the parallel group of 
AS patients, although direct comparison 
is clearly not possible, did experience a 
similar clinical benefit as in group C of 
the axOA patients (both groups received 
the HRS regimen), as assessed by means 
of VAS pain and disease specific BASMI, 
BASFI and BASDAI instruments, con-
firming previous reports (7). The over-
all analysis of the data emerging from 
the studies performed on spa therapy is 
difficult because they differ in terms of 
protocol, clinical profile of the recruited 
patients, differences in spa procedures, 
intensity and duration of treatment, as 
well as methods of assessments (18). 
Nevertheless, we can affirm that the avail-
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able evidence in the scientific literature 
suggests a clear therapeutic benefit of spa 
treatments in several musculoskeletal dis-
eases (29-32). In order to contribute to the 
understanding of the mechanisms respon-
sible for these beneficial effects reported 
by the patients, we also investigated the 
changes induced by MBT in serum pro-
tein profile.
In our wide-spectrum protein analysis 
we obtained, by direct antigen-labeling 
technology (Biotin Label-based Anti-
body Array), a broad and panoramic view 
of protein expression. Using this semi-
quantitative technique, up to 1000 target 
proteins were simultaneously detected, 
making this approach ideally suited for 
proteomic studies. We observed in both 
biological replicates increased levels (>2.5 
fold) of: inhibin beta A subunit (INHBA), 
activin A receptor type 2B (ACVR2B), 
Angiopoietin-1 (ANGPT1), beta-2-mi-
croglobulin (B2M), growth differentiation 
factor 10 (BMP-3b/GDF10), C-X-C mo-
tif chemokine ligand 5 (CXCL5), fibro-
blast growth factor 2 (FGF2), fibroblast 
growth factor 12 (FGF12), oxidized low 
density lipoprotein receptor 1 (OLR1), 
matrix metallopeptidase 13 (MMP13). We 
observed that some increased proteins be-
longs to the same family or pathway: IN-
HBA, ACVR2B and BMP-3b are members 
of TGF-Beta superfamily; CXCL5 and 
MMP13 participate in the IL-17 signaling 
pathway; FGF2 and FGF12 are proteins of 
FGF family. Among the three decreased 
proteins (≤0.65 fold) we underline the key 
role played by interleukin-23 in immune 
mediated diseases (30), and the role of 
apolipoprotein C-III (Apoc3) and synde-
can-1 (SDC1) in triglyceride and intersti-
tial matrix physiology.
Although it is not possible to speculate as 
to a specific role for each dysregulated pro-
tein in the beneficial effect of MBT, these 
results are extremely interesting because 
they show that MBT may induce changes 
in proteins involved in functions such as 
modulation of gene expression, cell dif-
ferentiation, angiogenesis and tissue repair, 
acute and chronic inflammatory response. 
In this regard, it is of note that some of 
these proteins may also be linked by 
physiologic interactions, as shown by the 
in silico analysis of associations between 
multiple proteins in Figure 1. For a precise 
description of a protein’s function, knowl-
edge about its interactions with other pro-
teins is clearly important. We have adopted 
the STRING software as a tool to derive 
functional associations, likely contributing 
to a common biological purpose. Interac-
tions were derived from:
1) known experimental interactions ob-
tained from scientific databases;
2) pathway knowledge from database;
3) text-miming to uncover links between 
proteins based on Medline search;
4) predicted interactions using genomic 
information (33, 34).
These data need to be interpreted in the 
context of all the data available in the lit-
erature, and represent a first approach to 
an omic strategy in the study of spa treat-
ments. The wide-spectrum analysis, ob-
tained from the semi-quantitative array 
that we employed, allows detection only 
of great changes, therefore small (but 
eventually important) physiological vari-
ations of other proteins have not been de-
tected. In this regard, several studies have 
provided evidence for the protective role 
of spa treatments on cartilage and bone 
by means of a significant reduction in 
serum levels of IL-1, TNF-α (35), PGE2 
and LTB4 (36), which are key cytokines 
in the joint inflammatory milieu and are 
also involved in osteoclast recruitment 
and bone reabsorption pathways. Moreo-
ver, it has been shown that MBT increase 
serum levels of osteocalcin (bone GLA 
protein, BGP), produced by osteoblasts, 
and bone alkaline phosphatase, both con-
sidered markers of bone metabolism (37). 
Several authors have also reported chang-
es in markers of cartilage degradation and 
circulating levels of adiponectin, resistin 
and visfatin after MBT in patients with 
OA (38).
Taking all these data together, we may as-
sume that the chemical properties of min-
eral water, together with mechanical and 
thermal effects (12), may explain, at least 
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in part, the clinical benefits and serum 
protein changes observed in our cohort of 
patients, as well as in real life rheumatic 
patients (39). In the attempt to clarify the 
mechanism of action of spa treatments we 
should also consider the pain control theory 
(40, 41), the result of hydrostatic pressure 
on blood circulation as well as the impact 
on muscle spasm of the heat, all mecha-
nisms which may mediate pain reduction 
and function improvement (42, 43). Hy-
drotherapy and balneotherapy have been 
also reported to exert beneficial effects on 
mood, anxiety and depression, therefore 
contributing to the amelioration of pain and 
general quality of life scores (44), although 
our data do not show an improvement in 
SF-36 MC index.
Limitations of the study
The main objective of the study was to eval-
uate protein changes following MBT and 
therefore we acknowledge that the number 
of patients enrolled is limited for a pure 
clinical study. The cohort was analyzed 
according to a single-blind method and 
therefore the patients were aware of their 
treatment regime. The assessment was also 
based on self-reported questionnaires and 
therefore the placebo effects could not be 
weighted. Furthermore, the wide-spectrum 
analysis by a semi-quantitative technique 
was not able to detect small changes in 
proteins which may have biological impor-
tance.
To sum up, the data emerging from this 
study, although with the limitations pre-
viously listed, confirm that spa therapy 
appears to be beneficial for chronic back 
pain, probably by means of different mech-
anisms, and to induce changes in proteins 
involved in functions such as gene expres-
sion modulation, cell differentiation, an-
giogenesis, tissue repair, acute and chronic 
inflammatory response. 
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APPENDIX
RayBio® L-Series Human Antibody Array 1000 probed with serum samples. The images of the glasses were captured using an Axon GenePix laser 
scanner. The strong signals in row 20 and the upper left and lower right corners of each array are Positive Controls, which can be used to identify 
the orientation and help normalize the results between arrays.
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Full list of proteins tested with “Human L1000 Array, Glass Slide” (RayBiotech): Target Name
11b-HSD1, 2B4, 4-1BB, 6Ckine, A1BG, A2M, ABL1, ACE, ACE-2, ACK1, ACPP, ACTH, Activin A, Activin B, Activin 
C, Activin RIA / ALK-2, Activin RIB / ALK-4, Activin RII A/B, Activin RIIA, ADAM-9, ADAMTS-1, ADAMTS-10, 
ADAMTS-13, ADAMTS-15, ADAMTS-17, ADAMTS-18, ADAMTS-19, ADAMTS-4 , ADAMTS-5, ADAMTS-L2, 
Adiponectin / Acrp30, Adipsin, Afamin, AFP, AgRP, ALBUMIN, ALCAM, Aldolase A, Aldolase B, Aldolase C, ALK, 
Alpha 1 AG, Alpha 1 Microglobulin, Alpha Lactalbumin, ALPP, AMICA, AMPKa1, Amylin, Angiogenin, Angiopoietin-1, 
Angiopoietin-2, Angiopoietin-4, Angiopoietin-like 1, Angiopoietin-like 2, Angiopoietin-like Factor, Angiostatin, 
ANGPTL3, ANGPTL4, Annexin A7, APC, APCS, Apelin, Apex1, APJ, APN, ApoA1, ApoA2, ApoA4, ApoB, ApoB100, 
ApoC1, ApoC2, ApoC3, ApoD, ApoE, ApoE3, ApoH, ApoM, APP, APRIL, AR (Amphiregulin), Artemin, ASPH, 
Attractin, Axl, B3GNT1, B7-1 /CD80, BACE-1, BAF57, BAFF, BAFF R / TNFRSF13C, BAI-1, bax, BCAM, BCMA / 
TNFRSF17, BD-1, BDNF, Beta 2M, Beta Defensin 4, Beta IG-H3, beta-Catenin, beta-NGF, Biglycan, BIK, BLAME, 
BLC / BCA-1 / CXCL13, BMP-15, BMP-2, BMP-3, BMP-3b / GDF-10, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, 
BMP-9, BMPR-IA / ALK-3, BMPR-IB / ALK-6, BMPR-II, BMX, BNIP2, BNP, BTC, Btk, C2, C3a, C5/C5a, C7, C8B, 
C9, CA125, CA15-3, CA19-9, CA9, Cadherin-13, Calbindin, Calbindin D, Calcitonin, Calreticulin, Calsyntenin-1, 
Cardiotrophin-1 / CT-1, CART, Caspase-3, Caspase-8, Cathepsin B, Cathepsin D, Cathepsin L, Cathepsin S, CBP, 
CCK, CCL14 / HCC-1 / HCC-3, CCL28 / VIC, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CD 
163, CD14, CD200, CD23, CD24, CD27 / TNFRSF7, CD30 / TNFRSF8, CD30 Ligand / TNFSF8, CD36, CD38, CD40 
/ TNFRSF5, CD40 Ligand / TNFSF5 /CD154, CD44, CD45, CD46, CD47, CD55, CD59, CD61, CD71, CD74, CD79 
alpha, CD90, CD97, CEA, CEACAM-1, Cerberus 1, Ceruloplasmin, CFHR2, Chem R23, Chemerin, CHI3L1, 
Chordin-Like 1, Chordin-Like 2, Chromogranin A, Chymase, cIAP-2, Ck beta 8-1, CK-MB, Claudin-3, Claudin-4, 
CLC, CLEC3B, Clusterin, CNDP1, CNTF R alpha, CNTF, Coagulation Factor III / Tissue Factor, Coagulation Factor 
X/Xa, COCO, Complement factor H, Contactin-1, Contactin-2, Corticosteroid-binding globulin, COX-2, C-peptide, 
CPN2, Creatinine, CRIM 1, Cripto-1, CRP, CRTAM, CRTH-2, Cryptic, CSH1, Csk, CTACK / CCL27, CTGF / CCN2, 
CTLA-4 /CD152, cTnT / Troponin T, CutA, CV-2 / Crossveinless-2, CXCL14 / BRAK, CXCL16, CXCR1 / IL-8 RA, 
CXCR2 / IL-8 RB, CXCR3, CXCR4 (fusin), CXCR5 /BLR-1, CXCR6, Cyclin D1, Cystatin A, Cystatin B, Cystatin C, 
Cytochrome C, Cytokeratin 8, Cytokeratin18, Cytokeratin19, D6, DAN, DANCE, DBI, DCBLD2, DcR3 / TNFRSF6B, 
D-Dimer, Decorin, DEFA1/3, Defensin, Desmin, Dkk-1, Dkk-3, Dkk-4, DLL1, DLL4, DMP-1, DPPIV, DR3 / TNFRSF25, 
DR6 / TNFRSF21, Dtk, E-Cadherin, EDA-A2, EDAR, EDG-1, EGF, EGF R / ErbB1, EG-VEGF / PK1, EMAP-II, ENA-
78, Endocan, Endoglin / CD105, Endorphin Beta, Endostatin, Endothelin, Endothelin Receptor A, Enolase 2, 
ENPP2, EN-RAGE, Eotaxin / CCL11, Eotaxin-2 / MPIF-2, Eotaxin-3 / CCL26, EpCAM, EphA1, EphA2, EphA3, 
EphA4, EphA5, EphA6, EphA7, EphA8, EphB1, EphB2, EphB3, EphB4, EphB6, Epiregulin, ErbB2, ErbB3, ErbB4, 
ERRa, Erythropoietin R, Erythropoietin, ESAM, E-Selectin, EV15L, EXTL2, FABP1, FABP2, FABP3, FABP4, Factor 
XIII A, Factor XIII B, FADD, FAK, FAM3B, FAP, Fas / TNFRSF6, Fas Ligand, Fc RIIB/C, Fen 1, FER, Ferritin, Fetuin A, 
Fetuin B, FGF Basic, FGF R3, FGF R4, FGF R5, FGF-10 / KGF-2, FGF-11, FGF-12, FGF-13 1B, FGF-16, FGF-17, 
FGF-18, FGF-19, FGF-20, FGF-21, FGF-23, FGF-4, FGF-5, FGF-6, FGF-7 / KGF, FGF-8, FGF-9, FGF-BP, FGFR1, 
FGFR1 alpha, FGFR2, Fibrinogen, Fibrinopeptide A, Fibronectin, Ficolin-3, FIH, FLRG, Flt-3 Ligand, Follistatin, 
Follistatin-like 1, FOLR1, FOXN3, FoxO1, FoxP3, Fractalkine, Frizzled-1, Frizzled-3, Frizzled-4, Frizzled-5, 
Frizzled-6, Frizzled-7, FRK, FSH, Furin, Fyn,” GADD45A, Galanin, Galectin-1, Galectin-3, Galectin-3BP, Galectin-7, 
gamma-Thrombin, Gas1, GASP-1 / WFIKKNRP, GASP-2 / WFIKKN, Gastrin, GATA-3, GATA-4, GCP-2 / CXCL6, 
GCSF, G-CSF R / CD 114, GDF1, GDF11, GDF-15, GDF3, GDF5, GDF8, GDF9, GDNF, Gelsolin, GFR alpha-1, GFR 
alpha-2, GFR alpha-3, GFR alpha-4, Ghrelin, GITR / TNFRF18, GITR Ligand / TNFSF18, GLO-1, GLP-1, Glucagon, 
Glut1, Glut2, Glut3, Glut5, Glypican 3, Glypican 5, GM-CSF, GM-CSF R alpha, GMNN, GPBB, GPI, GPR-39, GPX1, 
GPX3, Granzyme A, Grb2, GREMLIN, GRO, GRO-a, Growth Hormone (GH), Growth Hormone R (GHR), GRP, 
GRP75, GRP78, GSR, GST, HADHA, HAI-1, HAI-2, Haptoglobin, HB-EGF, HCC-4 / CCL16, hCG alpha, hCGb, Hck, 
HCR / CRAM-A/B, HE4, Hemopexin, Hepassocin, Hepcidin, HGF, HGFR, HOXA10, HRG-alpha, HRG-beta 1, 
HSP10, HSP20, HSP27, HSP32, HSP40, HSP60, HSP70, HSP90, HSPA8, HTRA2, HVEM / TNFRSF14, I-309, IBSP, 
ICAM-1, ICAM-2, ICAM-3 (CD50), ICAM-5, IFN-alpha / beta R1, IFN-alpha / beta R2, IFN-beta, IFN-gamma, IFN-
gamma R1, IGF2BP1, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-6, IGFBP-rp1 / IGFBP-7, IGF-I, 
IGF-I SR, IGF-II, IGF-II R, IL-1 alpha, IL-1 beta, IL-1 F10 / IL-1HY2, IL-1 F5 / FIL1delta, IL-1 F6 / FIL1 epsilon, IL-1 
F7 / FIL1 zeta, IL-1 F8 / FIL1 eta, IL-1 F9 / IL-1 H1, IL-1 R3 / IL-1 R AcP, IL-1 R4 /ST2, IL-1 R6 / IL-1 Rrp2, IL-1 R8, 
IL-1 R9, IL-1 ra, IL-1 sRI, IL-1 sRII, IL-10, IL-10 R alpha, IL-10 R beta, IL-11, IL-12 p40, IL-12 p70, IL-12 R beta 1, 
IL-12 R beta 2, IL-13, IL-13 R alpha 1, IL-13 R alpha 2, IL-15, IL-15 R alpha, IL-16, IL-17, IL-17B, IL-17B R, IL-17C, 
IL-17D, IL-17E, IL-17F, IL-17R, IL-17RC, IL-17RD, IL-18 BPa, IL-18 R alpha /IL-1 R5, IL-18 R beta /AcPL, IL-19, 
IL-2, IL-2 R alpha, IL-2 R beta /CD122, IL-2 R gamma, IL-20, IL-20 R alpha, IL-20 R beta, IL-21, IL-21 R, IL-22, IL-
22 BP, IL-22 R, IL-23, IL-23 R, IL-23p19, IL-24, IL-26, IL-27, IL-28A, IL-29, IL-3, IL-3 R alpha, IL-31, IL-31 RA, IL-33, 
IL-34, IL36RN, IL-4, IL-4 R, IL-5, IL-5 R alpha, IL-6, IL-6 R, IL-7, IL-7 R alpha, IL-8, IL-9 , INSL3, INSRR, Insulin, 
Insulin R, Insulysin / IDE, Integrin alpha V, IP-10, I-TAC / CXCL11, Itk, ITM2B, Kallikrein 10, Kallikrein 11, Kallikrein 
14, Kallikrein 2, Kallikrein 5, Kallikrein 6, Kallikrein 7, Kallikrein 8, KCC3, KCTD10, KIF3B, Kininostatin / kininogen, 
KLF4, Kremen-1, Kremen-2, LAG-3, Latent TGF-beta bp1, Layilin, LBP, Lck, LDL R, LECT2, Lefty - A, Legumain, 
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Leptin (OB), Leptin R, LFA-1 alpha, LH, LIF R alpha, LIF, LIGHT / TNFSF14, LIMPII, LIN41, Lipocalin-1, Livin, LOX-1, 
LPS, LRG1, LRP-1, LRP-6, L-Selectin (CD62L), LTF, LTK, Luciferase, Lumican, Lymphotactin / XCL1, Lymphotoxin 
beta / TNFSF3, Lymphotoxin beta R / TNFRSF3, Lyn, LYRIC, LYVE-1, LZTS1, MAC-1, Mammaglobin A, Marapsin, 
MATK, MBL, MBL-2, MCP-1, MCP-2, MCP-3, MCP-4 / CCL13, M-CSF, M-CSF R, MDC, Mer, Mesothelin, MFG-E8, 
MFRP, MICB, Midkine, MIF, MIG, MINA, MIP 2, MIP-1a, MIP-1b, MIP-1d, MIP-3 alpha, MIP-3 beta, MMP-1, MMP-
10, MMP-11 /Stromelysin-3, MMP-12, MMP-13, MMP-14, MMP-15, MMP-16 / MT3-MMP, MMP-19, MMP-2, 
MMP-20, MMP-24 / MT5-MMP, MMP-25 / MT6-MMP, MMP-3, MMP-7, MMP-8, MMP-9, MSHa, MSP alpha Chain, 
MSP beta-chain, MTUS1, Musk, Myoglobin, NAIP, Nanog, NAP-2, NCAM-1 / CD56, NELL2, NEP, Nesfatin, Nestin, 
NET1, Netrin G2, Netrin-4, Neuritin, NeuroD1, Neurokinin-A, Neuropeptide Y, Neuropilin-2, Neurturin, NF1, NGF R, 
NM23-H1/H2, Notch-1, NOV / CCN3, NPTX1, NPTXR, NR3C3, NRG1 Isoform GGF2, NRG1-alpha / HRG1-alpha, 
NRG1-beta1 / HRG1-beta1, NRG2, NRG3, NT-3, NT-4, Ntn1, OCT3/4, Omentin, Orexin A, Orexin B, OSM, 
Osteoactivin / GPNMB, Osteocalcin, Osteocrin, Osteopontin, Osteoprotegerin / TNFRSF11B, OX40, OX40 Ligand 
/ TNFSF4, p21, p27, p53, PAI-1, PAK7, Pancreastatin, Pancreatic Polypeptide, Pappalysin-1, PARC / CCL18, 
PARK7, P-Cadherin, PCAF, PD-1, PD-ECGF, PDGF R alpha, PDGF R beta, PDGF-AA, PDGF-AB, PDGF-BB, 
PDGF-C, PDGF-D, PDX-1, PECAM-1 /CD31, PEDF , Pentraxin3 / TSG-14, PEPSINOGEN I, PEPSINOGEN II, 
Peroxiredoxin 6 (Prdx6), Persephin, PF4 / CXCL4, PGRP-S, PI 16, PI 3Kinase p85 beta, PIM2, PKM2, Plasminogen, 
PlGF, PLUNC, Podocalyxin, POMC, PON1, PON2, PPARg2, PPP2R5C, Pref-1, Presenilin 1, Presenilin 2, Pro-BDNF, 
Procalcitonin, Pro-Cathepsin B, Progesterone, pro-Glucagon, Progranulin, Prohibitin, Prolactin, Pro-MMP-13, Pro-
MMP-7, Pro-MMP-9, ProSAAS, Prostasin, Protein p65, PSA-Free, PSA-total, P-selectin, PSP, PTH, PTHLP, PTN, 
PTPRD, PYK2, PYY, RAGE, RANK / TNFRSF11A, RANTES, Ras, RBP4, RECK, RELM alpha, RELM beta, RELT / 
TNFRSF19L, Resistin, RET, RIP1, ROBO4, ROCK1, ROCK2, ROR1, ROR2, ROS, RYK, S100 A8/A9, S100A10, 
S100A4, S100A6, S100A8, S-100b, SAA, SART1, SART3, SCF, SCF R /CD117, SCG3, SDF-1 / CXCL12, 
Selenoprotein P, SEMA3A, Serotonin, Serpin A1, Serpin A12, Serpin A3, Serpin A4, Serpin A5, Serpin A8, Serpin A9, 
Serpin B5, Serpin D1, Serpin I1, SERTAD2, sFRP-1, sFRP-3, sFRP-4, sgp130, SHBG, SIGIRR, Siglec-5/CD170, 
Siglec-9, SLPI, SMAC, Smad 1, Smad 4, Smad 5, Smad 7, Smad 8, SNCG, Soggy-1, Somatotropin, Sonic 
Hedgehog (Shh N-terminal), SOST, SOX17, SOX2, SPARC, SPARCL1, Spinesin, SPINK1, SRMS, SSEA-1, SSEA-4, 
SSTR2, SSTR5, Survivin, SYK, Syndecan-1, Syndecan-3, TACE, TACI / TNFRSF13B, TAF4, Tarc, TCCR / WSX-1, 
Tec, TECK / CCL25, TFF1, TFF3, TFPI, TGF-alpha, TGF-beta 1, TGF-beta 2, TGF-beta 3, TGF-beta 5, TGF-beta RI 
/ ALK-5, TGF-beta RII, TGF-beta RIII, Thrombin, Thrombomodulin, Thrombopoietin (TPO), Thrombospondin-1, 
Thrombospondin-2, Thrombospondin-4, Thymidine Kinase-1, Thymopoietin, Thyroglobulin, Thyroid Peroxidase 
(TPX), Tie-1, Tie-2, TIM-1, TIMP-1, TIMP-2, TIMP-3, TIMP-4, TL1A / TNFSF15, TLR1, TLR2, TLR3, TLR4, TMEFF1 
/ Tomoregulin-1, TMEFF2, TNF RI / TNFRSF1A, TNF RII / TNFRSF1B, TNF-alpha, TNF-beta, TNK1, TOPORS, TPA, 
TPM1, TRA-1-60, TRA-1-81, TRADD, TRAIL R1 / DR4 / TNFRSF10A, TRAIL R2 / DR5 / TNFRSF10B, TRAIL R3 / 
TNFRSF10C, TRAIL R4 / TNFRSF10D, TRAIL / TNFSF10, TRANCE, Transferrin, Trappin-2, TREM-1, TRKB, Troponin 
C, Troponin I, TROY / TNFRSF19, TRPC1, TRPC6, TRPM7, Trypsin 1, TSG-6, TSH, TSLP, TSLP, TWEAK / TNFSF12, 
TWEAK R / TNFRSF12, TXK, Tyk2, TYRO10, Ubiquitin+1, uPA, uPAR, Uromodulin, Vasopressin, Vasorin, VCAM-1 
(CD106), VDUP-1, VE-Cadherin, VEGF, VEGF R1, VEGF R2 (KDR), VEGF R3, VEGF-B, VEGF-C, VEGF-D, VEGI / 
TNFSF15, VGF, VIP Receptor 2, Visfatin, Vitamin D Receptor, Vitamin D-BP, Vitamin K-dependent protein S, 
Vitronectin, VWF, WIF-1, Wilms Tumor 1, WISP-1 / CCN4, XEDAR, XIAP, ZAG, ZAP70
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